Nidan, It is obvious that Biogen is not going to give up its core business in M/S treatment to its competitors (see link in my last post on the subject). They are focusing on patient analysis and biomarkers to increase their drugs efficiecies. Despite the deletion of their lab video emphasizing the forward path in M/S being remyelination, I still think that's their number 1 goal. This is evident in their moving forward with Opicinumab where they have had poor P2 results in remyelination of the optic nerve. Notice that they will be talking about patient subgroups and reevaluating the P2 data in and effort to see where they can carve out some efficacy. IMHO, there is too much remyelination potential in 2-73 for them to let it slip through their hands. CM, Tom and Dan are driving or have driven a very hard bargain. With a little patience we soon shall see.
News 
Market Data 
Discover 
